Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rhabdoid Tumor 6Wilms Tumor 5Sarcoma 5Osteosarcoma 5Neuroectodermal Tumors, Primitive, Peripheral 5Neuroblastoma 5Medulloblastoma 5Lymphoma, Non-Hodgkin 5Histiocytosis, Langerhans-Cell 5Hepatoblastoma 5Glioma 5Ependymoma 5Rhabdomyosarcoma 4Central Nervous System Neoplasms 4Neoplasm Metastasis 3Sarcoma, Ewing 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neuroendocrine Tumors 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Burkitt Lymphoma 2Xanthogranuloma, Juvenile 1Thyroid Cancer, Papillary 1Ovarian Neoplasms 1Non functioning pancreatic endocrine tumor 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Lymphoma 1Immunoglobulin Light-chain Amyloidosis 1Histiocytic Sarcoma 1

Interventions

Nivolumab 3Specimen Handling 2Magnetic Resonance Spectroscopy 2X-Rays 1Watchful Waiting 1Taxes 1Sigmoidoscopy 1Proctoscopy 1Phantoms, Imaging 1Paclitaxel 1Observation 1Ipilimumab 1Colonoscopy 1Carboplatin 1CTLA-4 Antigen 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anal Canal Carcinoma × Phantoms, Imaging × 30 days × Clear all
NCT03233711 2026-05-29

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
344 enrolled
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡